申请人:Glaxo Group Limited
公开号:US07622464B2
公开(公告)日:2009-11-24
Compounds of formula (I):
wherein:
R1 represents substituted or unsubstituted heteroaryl;
Y represents —(CRnaRnb)n—;
Rna and Rnb are each independently hydrogen or C1-6alkyl;
n is an integer from 0 to 5;
R2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;
R3 and R4 each independently represent hydrogen or C1-6-alkyl;
R7 represents hydrogen or C1-6alkyl;
R8 represents hydrogen or C1-6alkyl;
and salts and solvates thereof;
are CCR3 antagonists and are thus indicated to be useful in therapy.
化合物的公式(I):
其中:
R1代表取代或未取代的杂环芳基;
Y代表—(CRnaRnb)n—;
Rna和Rnb各自独立地代表氢或C1-6烷基;
n是从0到5的整数;
R2代表未取代或取代的芳基或未取代或取代的杂环芳基;
R3和R4各自独立地代表氢或C1-6烷基;
R7代表氢或C1-6烷基;
R8代表氢或C1-6烷基;
以及它们的盐和溶剂化物;
是CCR3拮抗剂,因此在治疗中有用。